PL2930169T3 - Krystaliczna postać chidamidu, sposób jej wytwarzania i zastosowanie - Google Patents
Krystaliczna postać chidamidu, sposób jej wytwarzania i zastosowanieInfo
- Publication number
- PL2930169T3 PL2930169T3 PL12889061T PL12889061T PL2930169T3 PL 2930169 T3 PL2930169 T3 PL 2930169T3 PL 12889061 T PL12889061 T PL 12889061T PL 12889061 T PL12889061 T PL 12889061T PL 2930169 T3 PL2930169 T3 PL 2930169T3
- Authority
- PL
- Poland
- Prior art keywords
- chidamide
- preparation
- crystal form
- crystal
- Prior art date
Links
- 229950009221 chidamide Drugs 0.000 title 1
- 239000013078 crystal Substances 0.000 title 1
- WXHHICFWKXDFOW-BJMVGYQFSA-N n-(2-amino-5-fluorophenyl)-4-[[[(e)-3-pyridin-3-ylprop-2-enoyl]amino]methyl]benzamide Chemical compound NC1=CC=C(F)C=C1NC(=O)C(C=C1)=CC=C1CNC(=O)\C=C\C1=CC=CN=C1 WXHHICFWKXDFOW-BJMVGYQFSA-N 0.000 title 1
- 238000002360 preparation method Methods 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/81—Amides; Imides
- C07D213/82—Amides; Imides in position 3
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4406—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 3, e.g. zimeldine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/54—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/54—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/56—Amides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Dermatology (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyridine Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201210489178.8A CN103833626B (zh) | 2012-11-27 | 2012-11-27 | 西达本胺的晶型及其制备方法与应用 |
| PCT/CN2012/086841 WO2014082354A1 (zh) | 2012-11-27 | 2012-12-18 | 西达本胺的晶型及其制备方法与应用 |
| EP12889061.3A EP2930169B1 (en) | 2012-11-27 | 2012-12-18 | Crystal form of chidamide, preparation method and use thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL2930169T3 true PL2930169T3 (pl) | 2018-12-31 |
Family
ID=50797567
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL12889061T PL2930169T3 (pl) | 2012-11-27 | 2012-12-18 | Krystaliczna postać chidamidu, sposób jej wytwarzania i zastosowanie |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US9573901B2 (pl) |
| EP (1) | EP2930169B1 (pl) |
| JP (1) | JP6387011B2 (pl) |
| KR (1) | KR20150082490A (pl) |
| CN (1) | CN103833626B (pl) |
| AU (1) | AU2012395573C1 (pl) |
| BR (1) | BR112015011898B1 (pl) |
| CA (1) | CA2891006C (pl) |
| DK (1) | DK2930169T3 (pl) |
| ES (1) | ES2691395T3 (pl) |
| HR (1) | HRP20181704T1 (pl) |
| HU (1) | HUE040649T2 (pl) |
| PL (1) | PL2930169T3 (pl) |
| PT (1) | PT2930169T (pl) |
| RS (1) | RS57856B1 (pl) |
| RU (1) | RU2603138C1 (pl) |
| SI (1) | SI2930169T1 (pl) |
| WO (1) | WO2014082354A1 (pl) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI794171B (zh) | 2016-05-11 | 2023-03-01 | 美商滬亞生物國際有限公司 | Ｈｄａｃ抑制劑與ｐｄ-ｌ１抑制劑之組合治療 |
| TWI808055B (zh) | 2016-05-11 | 2023-07-11 | 美商滬亞生物國際有限公司 | Hdac 抑制劑與 pd-1 抑制劑之組合治療 |
| CN107868044B (zh) * | 2016-09-27 | 2020-10-16 | 深圳微芯生物科技股份有限公司 | 一种非溶剂化晶体及其制备方法与应用 |
| CN109985039A (zh) * | 2017-12-29 | 2019-07-09 | 深圳微芯生物科技股份有限公司 | 用于治疗白血病的联合用药物及其在制备用于治疗急性髓性白血病的药物中的用途 |
| CA3120206A1 (en) * | 2018-11-20 | 2020-05-28 | Shenzhen Chipscreen Biosciences Co., Ltd. | Application of chidamide |
| CN117797149A (zh) | 2018-11-20 | 2024-04-02 | 深圳微芯生物科技股份有限公司 | 西达本胺联合r-chop的应用及联合药物 |
| CN112294810B (zh) * | 2019-07-29 | 2024-03-01 | 深圳微芯生物科技股份有限公司 | 含有西达本胺和表面活性剂的药物组合物 |
| US11878009B2 (en) | 2019-09-10 | 2024-01-23 | Great Novel Therapeutics Biotech & Medicals Corporation | Anticancer combination of chidamide and celecoxib salts |
| WO2021046765A1 (en) * | 2019-09-11 | 2021-03-18 | Gnt Biotech & Medicals Corporation | An anticancer combination of chidamide and celecoxib |
| CN117597124A (zh) * | 2021-07-08 | 2024-02-23 | 深圳微芯生物科技股份有限公司 | 西奥罗尼及其联合用药治疗乳腺癌的用途 |
| CN119431228B (zh) * | 2024-10-29 | 2025-08-12 | 成都苑东生物制药股份有限公司 | 西达本胺晶型i及其制备方法 |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7244751B2 (en) * | 2003-02-14 | 2007-07-17 | Shenzhen Chipscreen Biosciences Ltd. | Histone deacetylase inhibitors of novel benzamide derivatives with potent differentiation and anti-proliferation activity |
| CN1284772C (zh) * | 2003-07-04 | 2006-11-15 | 深圳微芯生物科技有限责任公司 | 具有分化和抗增殖活性的苯甲酰胺类组蛋白去乙酰化酶抑制剂及其药用制剂 |
-
2012
- 2012-11-27 CN CN201210489178.8A patent/CN103833626B/zh active Active
- 2012-12-18 PT PT12889061T patent/PT2930169T/pt unknown
- 2012-12-18 ES ES12889061.3T patent/ES2691395T3/es active Active
- 2012-12-18 CA CA2891006A patent/CA2891006C/en active Active
- 2012-12-18 WO PCT/CN2012/086841 patent/WO2014082354A1/zh not_active Ceased
- 2012-12-18 PL PL12889061T patent/PL2930169T3/pl unknown
- 2012-12-18 EP EP12889061.3A patent/EP2930169B1/en active Active
- 2012-12-18 AU AU2012395573A patent/AU2012395573C1/en active Active
- 2012-12-18 US US14/646,371 patent/US9573901B2/en active Active
- 2012-12-18 RU RU2015123682/04A patent/RU2603138C1/ru active
- 2012-12-18 BR BR112015011898-4A patent/BR112015011898B1/pt active IP Right Grant
- 2012-12-18 HR HRP20181704TT patent/HRP20181704T1/hr unknown
- 2012-12-18 DK DK12889061.3T patent/DK2930169T3/en active
- 2012-12-18 HU HUE12889061A patent/HUE040649T2/hu unknown
- 2012-12-18 RS RS20181175A patent/RS57856B1/sr unknown
- 2012-12-18 KR KR1020157014782A patent/KR20150082490A/ko not_active Ceased
- 2012-12-18 JP JP2015543237A patent/JP6387011B2/ja active Active
- 2012-12-18 SI SI201231417T patent/SI2930169T1/sl unknown
Also Published As
| Publication number | Publication date |
|---|---|
| RU2603138C1 (ru) | 2016-11-20 |
| AU2012395573B2 (en) | 2016-11-17 |
| SI2930169T1 (sl) | 2018-11-30 |
| US9573901B2 (en) | 2017-02-21 |
| ES2691395T3 (es) | 2018-11-27 |
| HK1210176A1 (en) | 2016-04-15 |
| PT2930169T (pt) | 2018-10-30 |
| CN103833626A (zh) | 2014-06-04 |
| HUE040649T2 (hu) | 2019-03-28 |
| CN103833626B (zh) | 2015-11-25 |
| CA2891006C (en) | 2017-06-06 |
| BR112015011898A2 (pt) | 2017-07-11 |
| EP2930169A1 (en) | 2015-10-14 |
| CA2891006A1 (en) | 2014-06-05 |
| AU2012395573C1 (en) | 2017-10-05 |
| DK2930169T3 (en) | 2018-11-12 |
| BR112015011898B1 (pt) | 2021-11-16 |
| EP2930169B1 (en) | 2018-07-18 |
| AU2012395573A1 (en) | 2015-06-25 |
| HRP20181704T1 (hr) | 2018-12-28 |
| KR20150082490A (ko) | 2015-07-15 |
| JP2016500081A (ja) | 2016-01-07 |
| JP6387011B2 (ja) | 2018-09-05 |
| EP2930169A4 (en) | 2016-06-08 |
| US20150299126A1 (en) | 2015-10-22 |
| WO2014082354A1 (zh) | 2014-06-05 |
| RS57856B1 (sr) | 2018-12-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA201501858B (en) | Anti-mcam antibodies and associated methods of use | |
| PT3725807T (pt) | Anticorpos anti-cd47 e métodos de utilização destes | |
| EP2803657A4 (en) | CRYSTAL FORM OF PROSTAGLANDINANALOGA AND METHOD OF PREPARING THEREOF AND USE THEREOF | |
| EP2808318A4 (en) | CRYSTALLINE FORM OF PROSTAGLANDIN ANALOGUE, PROCESS FOR PREPARING SAME AND USE THEREOF | |
| SG11201504049VA (en) | Compounds and their methods of use | |
| EP2831195A4 (en) | MICROEMULSION REFLUX ADJUVANT COMPOSITION AND METHOD OF USE | |
| ZA201404675B (en) | Anti-lrp5 antibodies and methods of use | |
| SG11201502757QA (en) | Anti-c16orf54 antibodies and methods of use thereof | |
| PT2930169T (pt) | Forma cristalina de chidamida, método de preparação e a sua utilização | |
| ZA201504167B (en) | Processes for the preparation of 4-amino-3-halo-6- (substituted)picolinates and 4-amino-5-fluoro-3-halo-6- (substituted)picolinates | |
| SG11201408326TA (en) | Preparation method for perfluoro-2-methyl-3-pentanone and intermediate | |
| SG10201704883VA (en) | Syringe devices, components of syringe devices, and methods of forming components and syringe devices | |
| IL234492A (en) | Crystalline forms of 5α - androstane - 3 β, 56β, - triol and methods for their preparation | |
| ZA201408128B (en) | Etract of greyia radlkoferi and use thereof | |
| EP2870133A4 (en) | TETRAHYDRO ISOHUMULOD DERIVATIVES, METHOD FOR THE PREPARATION AND USE THEREOF | |
| IL238934A0 (en) | Methods for the preparation of phenyloxymethyl-nitro-imidazole derivatives and their use | |
| GB201222855D0 (en) | Lock Means and Method of Use Thereof | |
| GB201210201D0 (en) | Carton locking means and method of use thereof | |
| AU2012900650A0 (en) | Compounds and methods of their use |